Showing 8101-8110 of 9881 results for "".
- Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSUhttps://practicaldermatology.com/news/novartis-ligelizumab-receives-breakthrough-therapy-designation-in-csu/2460656/Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab
- New Merz and Candela Collab Announcedhttps://practicaldermatology.com/news/new-merz-candela-collab-announced/2460655/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales representatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally inte
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the f
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there ar
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Merz Aesthetics Calls for Entries for First-Ever Innovation Forumhttps://practicaldermatology.com/news/merz-aesthetics-calls-for-entries-for-first-ever-innovation-forum/2460618/Merz Aesthetics is launching its first-ever Innovation Forum with a call for abstract submissions seeking the most creative and inventive medical aesthetics abstracts from the next generation of researchers and healthcare professionals. The author of the winning abstrac
- Online Booking Functionality Comes to Demandforcehttps://practicaldermatology.com/news/online-booking-functionality-comes-to-demandforce/2460615/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche